Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation

BACKGROUND/AIMS: Current literature is lacking in studies comparing the incidence of adverse events (AEs) in patients with inflammatory bowel diseases (IBD) treated with adalimumab (ADA) or vedolizumab (VDZ) in a real-life scenario. Therefore, our primary aim was to compare the AEs occurring in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Barberio, Brigida, Savarino, Edoardo Vincenzo, Card, Timothy, Canova, Cristina, Baldisser, Francesco, Gubbiotti, Alessandro, Massimi, Davide, Ghisa, Matteo, Zingone, Fabiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831779/
https://www.ncbi.nlm.nih.gov/pubmed/34333908
http://dx.doi.org/10.5217/ir.2021.00037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831779/
https://www.ncbi.nlm.nih.gov/pubmed/34333908
http://dx.doi.org/10.5217/ir.2021.00037

Ejemplares similares